Just caught a pretty significant shocker in pharma news. Sanofi's board just decided not to renew Paul Hudson's contract as CEO after six years at the helm. His last day will be February 17, 2026, which is coming up fast. What's interesting here is the messaging - the board specifically cited the need for "increased rigor" in executing strategy, which is corporate speak for "we need to turn things around."

So here's the succession play: Belén Garijo is stepping in as the new CEO starting April 29, 2026. She's coming over from Merck KGaA where she was CEO - actually made history as the first woman leading a DAX40 company in Germany. During the transition, Olivier Charmeil will hold the fort as interim CEO. The board's betting that Garijo can bring fresh momentum to R&D productivity and innovation, which has apparently been a sore spot.

Why the sudden move? Hudson was brought in back in 2019 specifically to revive the drug pipeline and get the stock moving. But here's the problem - Sanofi got way too dependent on one drug: Dupixent, their eczema treatment. Even though it's crushing it sales-wise (4.2 billion euros in Q4 2025, up 32.2%), the company's facing a major cliff when it loses exclusivity. Their CFO basically admitted they can't offset that hit. That's a real problem when your star asset is about to face generic competition.

The vaccine segment's also been messy. Q4 saw vaccine sales drop 2.5% to 2 billion euros. Beyfortus was down 14.9% to 686 million euros, and the PPH vaccines (polio, pertussis, hib) fell 9.5% to 551 million - partly because fewer babies were born in key markets including China. Influenza and COVID vaccines did better, up 31.5%, but clearly not enough to offset the declines.

What's got investors watching closely is whether Sanofi can actually make amlitelimab work as Dupixent's successor. Early data looks promising for treating moderate-to-severe atopic dermatitis in patients 12 and up, but execution is everything. The market was definitely spooked by this CEO change - SNY dropped 6.25% in premarket trading to $46.17.

This feels like a classic case of a board saying "we need someone to fix this" rather than a smooth transition. Whether Garijo can actually turn the pipeline around and reduce that Dupixent dependency will be the real shocker to watch.